Table 1 Clinical and biochemical data at diabetes onset in our index cases and cases reported in the literature
|  | Case n° 1 | Case n° 2 | Changizzadeh et al. [9] | Gunawan et al. [10] | Lowe et al. [11] |
|---|---|---|---|---|---|
Age (years) / Gender | 60/M | 80/F | 42/M | 52/M | 54/M |
History of diabetes | T2DM | No | No | No | No |
Familial history of diabetes | No | No | No | NR | NR |
Neoplasia | Melanoma stage IV | Melanoma stage IV | Melanoma stage IV | Melanoma stage IV | Melanoma stage IV |
Prior corticosteroid administration | No | No | No | Yesa | Yesb |
ICI regimen | IPI (3 mg/kg) and NIVO (1 mg/kg) every 3 weeks | IPI (3 mg/kg) and NIVO (1 mg/kg) every 3 weeks | IPI (3 mg/kg) and NIVO (1 mg/kg) every 3 weeks | IPI (3 mg/kg) and NIVO (1 mg/kg) every 3 weeks | IPI (3 mg/kg) and NIVO (1 mg/kg) every 3 weeks |
Time to T1DM onset | 2 weeks (1 cycle) | 5 weeks (1 cycle) | 12 weeks (3 cycles) | 11 weeks (3 cycles) | 19 weeks (3 cycles) |
DKA | Yes | Yes | Yes | No | Yes |
Plasma glucose (mmol/L) | 46 | 48.4 | 40.4 | 20.8 | NR |
Ketones bodies (mmol/L) | |||||
 Plasma | NA | NA | NR | 2.4 | NR |
 Urine | > 7.8 | > 7.8 | NR | NR | 0.40 |
HbA1C (%) | 7.5 | NA | 6.5 | 7.7 | NR |
C-Peptide (nmol/L) | NA | NA | NR | 0.05 (N: 0.4–1.5) | NR |
T1DM-related autoantibodies | + (GADA, ICA, IA2) | + (GADA, ICA) IA2 - | - (GADA, IA2, ZnT8A) | - (GADA, IA2, ZnT8A) | (GADA) |
Other immune-related endocrine toxicities | None | Autoimmune thyroiditis | None | Hypophysitis, Diabetes insipidus | Autoimmune thyroiditis Hypophysitis |
Non endocrine immune related toxicities | Presumed immune-checkpoint inhibitor-induced pancreatic injury | None | Colitis | None | Hepatitis, Colitis |
Definitive discontinuation of ICI | Yes | Yes | Yes | Yes | Yes |